Evaluation of kidney function or markers of kidney damage in patients withconfirmed T2D should be done at the time of diagnosis and at least annuallythereafter by measurement of urinary albumin excretion (best done by a UACR) andserum creatinine with an eGFR (see Question 1).4 Upon diagnosis of DKD,patients should be offered a comprehensive strategy to reduce the risk of kidneydisease progression and prevent or reduce CV and vascular disease.41 Treatmentdecisions should be individualized based on patients’ cardiorenal risk,preferences, access and cost, and degree of glucose lowering needed.32 The gene discussed is ALB; the disease is type 2 diabetes mellitus.